“Alcon has a long legacy of advancing phaco and vitreoretinal technology for surgical ophthalmology. With UNITY VCS/CS, we are introducing more than a dozen innovations designed to transform surgical ...
Alcon agreed to buy LENSAR for $14.00/share cash, integrating ALLY, Streamline, and the legacy laser system to expand FLACS ...
The Federal Trade Commission said the transaction had threatened to raise prices and stifle innovation for cataract laser eye surgery systems.
Data on Alcon’s products across cataract, refractive, diagnostics and ocular health will be featured in presentations during the meeting Prospective analyses and studies demonstrate sustained ...
Lensar has some rebuilding to do now that a merger with Alcon has fallen through, according to a BTIG analyst. To recap, ...
GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today revealed final data from its Vivity ® Registry Study, which monitored ...
William Blair initiated coverage on Alcon Inc. (NYSE: ALC) on Friday with a Market Perform rating. Over the past two years, Alcon has been aggressive in driving top-line growth both internally ...
Aging is a natural part of life, and as we grow older, our bodies go through various changes. Our hair turns gray, our joints ache a bit more and our energy levels fluctuate. But one aspect of aging ...
LENSAR (NASDAQ:LNSR) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline how the ...
Alcon, the multinational pharmaceuticals company specializing in eye care, has agreed a deal to acquire cataract laser surgery pioneer Lensar. The deal, valued at up to $430 million, will expand Alcon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results